Myriad Genetics Posts 27 Percent Revenue Growth for Q3 | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its third-quarter 2012 revenues jumped 27 percent.

The Salt Lake City-based molecular diagnostics firm reported total revenues of $129.8 million for the three-month period ended March 31, up from $102.4 million for Q3 2011. It easily beat Wall Street's consensus estimate for revenues of $119.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.